Patients with end-stage renal disease (ESRD) are at risk of developing drug-related problems (DRPs) due to polypharmacy, multiple co-morbidities and frequent medication changes.
INtRODUCtION
Patients with end-stage renal disease (ESRD) are at risk of developing drug-related problems (DRPs) due to polypharmacy, multiple co-morbidities and frequent medication changes 1 . Pharmacists are in a unique position in a multidisciplinary healthcare team to identify and solve DRPs by conducting medication reconciliation and educating patients 2 . Medication reconciliation in ESRD patients is an effective process to reduce adverse drug events and harm associated with the loss of medication information as patients transfer between healthcare settings [3] [4] .
ObJECtIVE
In this report, we aim to evaluate the prevalence of DRPs identified and the types of interventions made by MMS pharmacists.
MEtHODOLOGY
Renal MMS, a pilot initiative by a team of MMS pharmacists and a renal physician, was set up to conduct comprehensive medication review and medication reconciliation in haemodialysis patients. Patients were selected based on inclusion criteria such as recent hospitalisation in three months, more than 10 medications, and recent changes to the list of medications. Selected patients received a phone call from renal coordinators with a request to bring along all their medications and to see the pharmacist before meeting the physician for their appointment. Prior to the meeting, the Proceedings of Singapore Healthcare  Volume 22  Number 2  2013 pharmacist would have assessed and analysed the latest blood results and drug history from our hospital's electronic database and records from the haemodialysis centre. During the review, the pharmacist will counsel the patients about their medications, assess their adherence and identify DRPs. A written report on the findings and proposed recommendations will be submitted to the referring physician to aid clinical decision making. This acts as a method of communication between the patient's dialysis centre, pharmacist and attending renal physician.
RESULtS
From January to May 2012, a total of 30 patients were enrolled into the service. This group of patients had an average of 12 medications prescribed to them. The breakdown of patients' demographics is shown in Table 1 . A fifth of the patients were financially supported by Medifund while the rest were self-paying.
On average, each patient had 3.1 DRPs. Studies have shown that DRPs were associated with increased hospitalisations and reduced quality of life [5] [6] . Approximately two thirds of the DRPs were solved by MMS pharmacists, with or without the physician's interventions.
The three most common DRPs, as shown in Figure 1 , were non-adherence (41.5%), untreated indication (14.9%) and adverse drug reactions (11.7%). In total, 54 interventions were performed by MMS pharmacists. Almost half of the interventions involved suggestions to modify dosing regimens (51.9%), followed by suggestions to add new drugs (16.7%) and to discontinue drugs (13.0%) as shown in Figure 2 . Approximately three out of every four interventions were accepted.
DISCUSSION
In total, 41.5% of our patients were found to be nonadherent to their medications. Patients reported "pill burden" as the commonest reason for nonadherence. This was not surprising as the average number of medications consumed per person in this population was 12.
Side-effects experienced with medications were also a reason for non-adherence. Commonly involved medications include phosphate binders, iron supplements and antihypertensive drugs. Phosphate binders such as calcium acetate and calcium carbonate that should be taken with meals were often blamed to adversely affect appetite. Iron supplements were often skipped due to the side-effect of constipation. Antihypertensive drugs were often self-adjusted by patients due to fluctuating blood pressure not uncommonly seen in dialysis patients. Our results are consistent with a study reporting non-adherence as the most common DRPs 7 in haemodialysis patients.
Most patients received recommendation to optimise therapy. Examples of optimisation include addition of medication to treat constipation, renal dosing adjustment, recommendation for an alternative phosphate binder for patients experiencing side-effects, discontinuation of duplicate drugs and so forth. The mean number of interventions per patient was 1.8 and the recommendation acceptance rate was 74.1%.
Our study has several limitations. It is a single centre study with a small sample size. As different pharmacists with diverse experience were scheduled to conduct the review, the consistency in findings may be affected by inter-reviewer variability. Based on the results of our study, we would like to recommend MMS to all haemodialysis patients to address the challenges of their dynamic medication therapy. With close supervision by pharmacists as part of the integrated multidisciplinary team, we hope to improve medication accuracy for patient care and safety. Nevertheless, a future prospective study needs to be performed to examine the impact of medication reconciliation towards patients' safety. 
CONCLUSION
In conclusion, ESRD patients are exposed to DRPs which increase the risk of hospitalisations and reduce quality of life. Medication reconciliation and optimisation of therapy conducted by pharmacists may address the gap in information when patients transfer between healthcare settings.
